Top

Cancer Chemotherapy and Pharmacology

Published in:

01-07-2013 | Original Article

Clinical potential of the anticancer drug sensitivity test for patients with synchronous stage IV colorectal cancer

Authors: Katsushi Takebayashi, Eiji Mekata, Hiromichi Sonoda, Tomoharu Shimizu, Yoshihiro Endo, Tohru Tani

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2013

Abstract

Purpose

We retrospectively evaluated the clinical efficacy and feasibility of a collagen gel droplet-embedded culture drug sensitivity test (CD-DST) to guide therapy for patients with stage IV colorectal cancer (CRC).

Methods

We investigated 38 patients with stage IV CRC. All patients were younger than 85 years and had untreated evaluable metastatic lesions. The primary tumors were surgically resected, and the tissue samples were investigated by CD-DST. Patients treated with in vitro sensitive drugs were defined as Group A (n = 14), while those treated with in vitro non-sensitive drugs were defined as Group B (n = 24). We evaluated response rate (RR), progression-free survival (PFS), and overall survival (OS).

Results

RR was 85.71 % in Group A and 41.67 % in Group B (p = 0.0079). The median PFS was 696.5 days in Group A and 297.5 days in Group B (p = 0.0326). The median OS was 1,023.4 days in Group A and 518.5 days in Group B (p = 0.0061).

Conclusions

The CD-DST can define chemoresistant and chemosensitive tumors. The use of CD-DST might be one of the tools to supplement informed consent prior to initiation of therapy.

Kindler HL, Shulman KL (2001) Metastatic colorectal cancer. Curr Treat Options Oncol 2:459–471PubMedCrossRef

Midgley R, Kerr D (2001) Conventional cytotoxic and novel therapeutic concepts in colorectal cancer. Expert Opin Investig Drugs 10:1011–1019PubMedCrossRef

Yasuda H, Takada T, Wada K et al (1998) A new in vitro drug sensitivity test (collagen-gel droplet embedded culture drug sensitivity test) in carcinomas of pancreas and biliary tract: possible clinical utility. J Hepatobiliary Pancreat Surg 5:261–268PubMedCrossRef

Ochiai T, Nishimura K, Noguchi H et al (2005) Evaluation of 5-fluorouracil applicability by multi-point collagen gel droplet embedded drug sensitivity test. Oncol Rep 14:201–205PubMed

Mori T, Ohnishi M, Komiyama M, Tsutsui A et al (2002) Prediction of cell kill kinetics of anticancer agents using the collagen gel droplet embedded-culture drug sensitivity test. Oncol Rep 9:301–305PubMed

Kobayashi H (2003) Development of a new in in vitro chemosensitivity test using collagen gel droplet embedded culture and image analysis for clinical usefulness. Recent Results Cancer Res 161:48–61PubMedCrossRef

Kobayashi H, Tanisaka K, Doi O et al (1997) An in vitro chemosensitivity test for solid human tumors using collagen gel droplet embedded cultures. Int J Oncol 11:449–455PubMed

Takamura Y, Kobayashi H, Taguchi T et al (2002) Prediction of chemotherapeutic response by collagen gel droplet embedded culture-drug sensitivity test in human breast cancers. Int J Cancer 98:450–455PubMedCrossRef

Poultsides GA, Servais EL, Saltz LB et al (2009) Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 27:3379–3384PubMedCrossRef

10.

Hanatani Y, Kobayashi H, Kodaira S et al (2000) An in vitro chemosensitivity test for gastric cancer using collagen gel droplet embedded culture. Oncol Rep 7:1027–1033PubMed

11.

Higashiyama M, Kodama K, Yokouchi H et al (2001) Cisplatin-based chemotherapy for postoperative recurrence in non-small cell lung cancer patients: relation of the in vitro chemosensitive test to clinical response. Oncol Rep 8:279–283PubMed

12.

Okumura K, Shiomi H, Mekata E et al (2006) Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer. Oncol Rep 15:875–882PubMed

13.

Shimizu T, Murata S, Mekata E et al (2007) Clinical potential of an anticancer drug sensitivity test and diffusion-weighted MRI in a patient with a recurrent solid pseudopapillary tumor of the pancreas. J Gastroenterol 42:918–922PubMedCrossRef

14.

Kawamura M, Gika M, Abiko T et al (2007) Clinical evaluation of chemosensitivity testing for patients with unresectable non-small cell lung cancer (NSCLC) using collagen gel droplet embedded culture drug sensitivity test (CD-DST). Cancer Chemother Pharmacol 59:507–513PubMedCrossRef

15.

Scheele J, Stang R, Altendorf-Hofmann A, Paul M (1995) Resection of colorectal liver metastasis. World J Surg 19:59–71PubMedCrossRef

16.

Adam R (2003) Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastasis. Ann Oncol 14:1113–1116CrossRef

17.

Kopetz S, Chang GJ, Overman MJ et al (2009) Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27:3677–3683PubMedCrossRef

18.

Saltz LB, Clarke S, Díaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019PubMedCrossRef

19.

Alberts SR, Horvath WL, Sternfeld WC et al (2005) Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastasis from colorectal cancer: a north central cancer treatment group phase II study. J Clin Oncol 23:9243–9249PubMedCrossRef

20.

Mizota A, Shitara K, Kondo C et al (2011) Retrospective analysis of cetuximab monotherapy for patients with irinotecan-intolerant metastatic colorectal cancer. Int J Oncol 16:416–420CrossRef

21.

Price TJ, Zannino D, Wilson K et al (2012) Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of capecitabine, bevacizumab and mitomycin C. Ann Oncol 23:1531–1536PubMedCrossRef

22.

Pessino A, Artale S, Sciallero S et al (2008) First-line single-agent cetuximab in patients with advanced colorectal cancer. Ann Oncol 19:711–716PubMedCrossRef

Title: Clinical potential of the anticancer drug sensitivity test for patients with synchronous stage IV colorectal cancer
Authors: Katsushi Takebayashi
Eiji Mekata
Hiromichi Sonoda
Tomoharu Shimizu
Yoshihiro Endo
Tohru Tani
Publication date: 01-07-2013
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 1/2013
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-013-2189-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2013

Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma

Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors

HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer

Anti-vascular endothelial growth factor therapy in the era of personalized medicine

Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer

Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer